Cancers 2012, 4(4), 1161-1179; doi:10.3390/cancers4041161
Review

The Development of Novel Therapies for the Treatment of Acute Myeloid Leukemia (AML)

Received: 22 August 2012; in revised form: 29 September 2012 / Accepted: 17 October 2012 / Published: 2 November 2012
(This article belongs to the Special Issue Leukemia)
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract: Acute myeloid leukemia (AML) is nearly always a fatal malignancy. For the past 40 years, the standard of care remains a combination of cytarabine and an anthracycline known as 7 + 3. This treatment regimen is troubled by both low survival rates (10% at 5 years) and deaths due to toxicity. Substantial new laboratory findings over the past decade have identified many cellular pathways that contribute to leukemogenesis. These studies have led to the development of novel agents designed to target these pathways. Here we discuss the molecular underpinnings and clinical benefits of these novel treatment strategies. Most importantly these studies demonstrate that clinical response is best achieved by stratifying each patient based on a detailed understanding of their molecular abnormalities.
Keywords: acute myeloid leukemia; targeted therapies; early phase trials
PDF Full-text Download PDF Full-Text [422 KB, uploaded 2 November 2012 11:50 CET]

Export to BibTeX |
EndNote


MDPI and ACS Style

Assouline, S.; Cocolakis, E.; Borden, K.L.B. The Development of Novel Therapies for the Treatment of Acute Myeloid Leukemia (AML). Cancers 2012, 4, 1161-1179.

AMA Style

Assouline S, Cocolakis E, Borden KLB. The Development of Novel Therapies for the Treatment of Acute Myeloid Leukemia (AML). Cancers. 2012; 4(4):1161-1179.

Chicago/Turabian Style

Assouline, Sarit; Cocolakis, Eftihia; Borden, Katherine L.B. 2012. "The Development of Novel Therapies for the Treatment of Acute Myeloid Leukemia (AML)." Cancers 4, no. 4: 1161-1179.

Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert